Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Semiconductor ETF (SOXX) vs BIO-TECHNE Corp (TECH) Price & Performance

iShares Semiconductor ETFTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

iShares Semiconductor ETF vs BIO-TECHNE Corp — how do they compare? iShares Semiconductor ETF trades at $530.32, while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares Semiconductor ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.

SOXXTECH
Sector
Sector/ThematicHealth
52-Week High
$655.01$72.48
52-Week Low
$253.45$43.31
Market Cap
$11.34B
Enterprise Value
$11.36B
Dividend Yield
0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Semiconductor ETF

SOXX, the iShares Semiconductor ETF, trades at $528.40, up 1.64% on the day, reflecting strong momentum driven by AI infrastructure demand. The technical outlook is bullish, with moving averages supporting an uptrend and key resistance at $533. Recent news highlights surging power demand in South Korea linked to chipmaker expansions and AI data centers, underscoring sector growth catalysts. A 1:3 stock split is scheduled for November 2026, potentially enhancing accessibility.

The ETF's outlook remains positive, fueled by robust AI-driven semiconductor demand and institutional inflows, though risks include potential tariff hikes and market volatility. Analysts are broadly optimistic, citing diversified exposure to top performers like Nvidia and AMD. Investors should weigh near-term overcrowding risks against long-term structural growth in AI and memory markets.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.

The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Semiconductor ETF

SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.

Read more on SOXX

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH